Johnson & Johnson earns FDA clearance, CE mark for next-gen phaco machine

The VERITAS™ Vision System is a modular ophthalmic microsurgical system that facilitates anterior segment (i.e., cataract) ophthalmic surgery. The modular design allows the users to configure the system to meet their surgical requirements. (Image courtesy of Johnson & Johnson Vision).

Johnson & Johnson Vision announced today that the FDA has granted 510(k) clearance and CE mark for its VERTIAS^TM Vision System, a next-generation phacoemulsification innovation.

The high-performance phacoemulsification system features advancements in ergonomics to further enhance surgeons’ usability during cataract surgery as well technologies to enable them to operate through any lens density with less surge and more stability, according to a company release.

While phacoemulsification as a technique has been successfully used decades, ease of use continues to be the unmet need with cataract surgeons, according to Rajesh K. Rajpal, MD, chief medical officer and global head of Clinical and Medical Affairs at Johnson & Johnson Vision.

““Every aspect of Johnson & Johnson Vision’s new VERITAS™ System was designed to give surgeons an excellent user experience – optimizing features for safety and efficiency, with improvements in two main areas: fluidics and ergonomics,” he said, in a statement.

This latest news from Johnson & Johnson follows the FDA approval of the TECNIS® EYHANCE and TECNIS® EYHANCE TORIC II IOLs for cataract patient treatment in the U.S. earlier this year, as well as the 20th anniversary of the company’s TECNIS® platform.

Read the early clinical experience of the physician who performed the first post-approval case using the TECNIS Eyhance and TECNIS Eyhance Toric II IOLs

The company expects to roll out a full commercial launch of the VERITAS™ Vision System later in the year, according to the release.

Read more cataract surgery and IOL content